UroGen Pharma has established a differentiated position in the niche urothelial cancer market through its proprietary reverse-thermal hydrogel (RTGel) technology, embodied in FDA-approved products Jelmyto and Zusduri. Despite initial revenue gains from product launches, 2025 saw significant revenue contraction alongside deepening operating losses caused by heavy investment in commercial infrastructure and ongoing R&D. The company’s upcoming patent litigation against Teva represents a critical inflection for exclusivity beyond 2027 when orphan drug protections expire. UroGen is expanding its U.S.-based specialized sales and medical affairs team to drive physician uptake amidst broad insurance coverage for its products but faces dependence on financing and regulatory uncertainties. Key milestones include the October 2026 patent trial and continued adoption monitoring of Zusduri.